MDBH — MDB Capital Holdings, LLC Class A common

MDB Capital Holdings Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Operating Expenses: Approximately $10 million, with a cash burn of $5.7 million for the year. After accounting for $4 million invested in MDB Direct and PatentVest, the adjusted cash burn was $1.7 million.
• Assets: At year-end, MDB's cash and current assets, minus liabilities, totaled about $22.3 million.
• Market Valuation: eXoZymes had a market valuation of approximately $30 million, while Paulex's valuation is yet to be determined pending its IPO.

2. Strategic Updates and Business Highlights

• IPO Success: MDB has successfully completed 18 IPOs, all trading at a premium to their IPO prices, except the most recent one.
• AI Integration: The company is leveraging AI to streamline operations, reduce the time for due diligence and IPO preparation from months to weeks, significantly enhancing scalability.
• MDB Direct and PatentVest: Investments of $4 million annually have established these as valuable independent assets. MDB Direct aims to capitalize on the changing landscape of IPO distribution, while PatentVest is transitioning into a law firm to enhance its service offerings.
• Portfolio Development: MDB is focusing on launching 3-5 companies annually, with a strong pipeline of opportunities in deep tech and life sciences.

3. Forward Guidance and Outlook

• Future Growth: The company aims to launch 3-5 high-quality companies per year, contingent on resolving distribution challenges.
• Spin-Out Plans: MDB plans to spin out both MDB Direct and PatentVest, with a potential public offering for PatentVest targeted for 2027.
• Market Potential: The leadership believes all principal assets have the potential for $1 billion valuations, which could significantly enhance shareholder value.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: The microcap market remains challenging, with concerns about dilution affecting small companies.
• Execution Risks: There are inherent risks associated with the execution of portfolio companies and the overall strategy, particularly in the competitive landscape of deep tech and life sciences.
• Distribution Gaps: The ability to effectively distribute new offerings is a critical concern, as the company currently has a small investor base with only 675 active accounts.

5. Notable Q&A Insights

• Portfolio Company Updates:
  • Cue Biopharma: Facing challenges in commercialization but has potential partnerships that could enhance its value.
  • eXoZymes: Positioned for minimal dilution due to efficient operations and government grants; expected to be a leader in biomanufacturing.
  • Buda Juice: Seen as a unique opportunity in the fresh juice market, with potential for significant growth.
• SaaS Model Discussion: Chris Marlett expressed skepticism about the viability of a SaaS model for PatentVest, suggesting that AI will fundamentally change how patent analysis is conducted, making traditional SaaS less relevant.
• Future Pipeline: The company is optimistic about its deal pipeline, emphasizing that the constraint is not the number of companies but the ability to secure distribution for them.

Overall, MDB Capital Holdings is optimistic about its future growth prospects, driven by strategic investments and the integration of AI, despite facing challenges in market conditions and execution risks.